Clinical Experience with Extended-Release Tacrolimus in Older Adult Kidney Transplant Recipients: A Retrospective Cohort Study
ConclusionsOlder adult recipients required significantly lower LCP-Tac doses compared with younger recipients and with the FDA-labeled starting dose. There were no differences in graft outcomes or adverse effects in older adult patients who received LCP-Tac versus IR-Tac.
Source: Drugs and Aging - Category: Geriatrics Source Type: research
More News: Alopecia | Cytomegalovirus | Diabetes | Endocrinology | Geriatrics | Hypertension | Kidney Transplant | Kidney Transplantation | Prograf | Study | Tacrolimus | Transplant Surgery | Transplants | Urology & Nephrology